Literature DB >> 23788640

FOG2 protein down-regulation by transforming growth factor-β1-induced microRNA-200b/c leads to Akt kinase activation and glomerular mesangial hypertrophy related to diabetic nephropathy.

Jung Tak Park1, Mitsuo Kato, Hang Yuan, Nancy Castro, Linda Lanting, Mei Wang, Rama Natarajan.   

Abstract

Glomerular hypertrophy is a hallmark of diabetic nephropathy. Akt kinase activated by transforming growth factor-β1 (TGF-β) plays an important role in glomerular mesangial hypertrophy. However, the mechanisms of Akt activation by TGF-β are not fully understood. Recently, miR-200 and its target FOG2 were reported to regulate the activity of phosphatidylinositol 3-kinase (the upstream activator of Akt) in insulin signaling. Here, we show that TGF-β activates Akt in glomerular mesangial cells by inducing miR-200b and miR-200c, both of which target FOG2, an inhibitor of phosphatidylinositol 3-kinase activation. FOG2 expression was reduced in the glomeruli of diabetic mice as well as TGF-β-treated mouse mesangial cells (MMC). FOG2 knockdown by siRNAs in MMC activated Akt and increased the protein content/cell ratio suggesting hypertrophy. A significant increase of miR-200b/c levels was detected in diabetic mouse glomeruli and TGF-β-treated MMC. Transfection of MMC with miR-200b/c mimics significantly decreased the expression of FOG2. Conversely, miR-200b/c inhibitors attenuated TGF-β-induced decrease in FOG2 expression. Furthermore, miR-200b/c mimics increased the protein content/cell ratio, whereas miR-200b/c inhibitors abrogated the TGF-β-induced increase in protein content/cell. In addition, down-regulation of FOG2 by miR-200b/c could activate not only Akt but also ERK, which was also through PI3K activation. These data suggest a new mechanism for TGF-β-induced Akt activation through FOG2 down-regulation by miR-200b/c, which can lead to glomerular mesangial hypertrophy in the progression of diabetic nephropathy.

Entities:  

Keywords:  Akt; Cell Signaling; Diabetes; FOG2; Hypertrophy; MicroRNA; Nephrology; Transforming Growth Factor β (TGFbeta)

Mesh:

Substances:

Year:  2013        PMID: 23788640      PMCID: PMC3829336          DOI: 10.1074/jbc.M113.453043

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  64 in total

Review 1.  Conserved cardiogenic functions of the multitype zinc-finger proteins: U-shaped and FOG-2.

Authors:  N Fossett; R A Schulz
Journal:  Trends Cardiovasc Med       Date:  2001-07       Impact factor: 6.677

2.  Signaling pathways and late-onset gene induction associated with renal mesangial cell hypertrophy.

Authors:  Sandro Goruppi; Joseph V Bonventre; John M Kyriakis
Journal:  EMBO J       Date:  2002-10-15       Impact factor: 11.598

3.  Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration.

Authors:  A V Bakin; A K Tomlinson; N A Bhowmick; H L Moses; C L Arteaga
Journal:  J Biol Chem       Date:  2000-11-24       Impact factor: 5.157

4.  Smad3 regulates E-cadherin via miRNA-200 pathway.

Authors:  S-M Ahn; J-Y Cha; J Kim; D Kim; H T H Trang; Y-M Kim; Y-H Cho; D Park; S Hong
Journal:  Oncogene       Date:  2011-10-24       Impact factor: 9.867

Review 5.  MicroRNA control of signal transduction.

Authors:  Masafumi Inui; Graziano Martello; Stefano Piccolo
Journal:  Nat Rev Mol Cell Biol       Date:  2010-03-10       Impact factor: 94.444

6.  Conserved MicroRNA miR-8/miR-200 and its target USH/FOG2 control growth by regulating PI3K.

Authors:  Seogang Hyun; Jung Hyun Lee; Hua Jin; JinWu Nam; Bumjin Namkoong; Gina Lee; Jongkyeong Chung; V Narry Kim
Journal:  Cell       Date:  2009-12-11       Impact factor: 41.582

Review 7.  The extracellular matrix in diabetic nephropathy.

Authors:  F N Ziyadeh
Journal:  Am J Kidney Dis       Date:  1993-11       Impact factor: 8.860

8.  Epithelial-restricted gene profile of primary cultures from human prostate tumors: a molecular approach to predict clinical behavior of prostate cancer.

Authors:  Simona Nanni; Carmen Priolo; Annalisa Grasselli; Manuela D'Eletto; Roberta Merola; Fabiola Moretti; Michele Gallucci; Piero De Carli; Steno Sentinelli; Anna Maria Cianciulli; Marcella Mottolese; Paolo Carlini; Diego Arcelli; Mauro Helmer-Citterich; Carlo Gaetano; Massimo Loda; Alfredo Pontecorvi; Silvia Bacchetti; Ada Sacchi; Antonella Farsetti
Journal:  Mol Cancer Res       Date:  2006-02       Impact factor: 5.852

Review 9.  TGF-beta in renal injury and disease.

Authors:  Erwin P Böttinger
Journal:  Semin Nephrol       Date:  2007-05       Impact factor: 5.299

10.  Sevoflurane-mediated TGF-beta1 signaling in renal proximal tubule cells.

Authors:  H Thomas Lee; Mihwa Kim; Joseph H Song; Sean W C Chen; Gina Gubitosa; Charles W Emala
Journal:  Am J Physiol Renal Physiol       Date:  2007-12-05
View more
  42 in total

Review 1.  MicroRNAs in diabetic nephropathy: functions, biomarkers, and therapeutic targets.

Authors:  Mitsuo Kato; Rama Natarajan
Journal:  Ann N Y Acad Sci       Date:  2015-04-15       Impact factor: 5.691

2.  MicroRNA-200 promotes lung cancer cell growth through FOG2-independent AKT activation.

Authors:  Lixia Guo; Jingyu Wang; Ping Yang; Qiang Lu; Ting Zhang; Yanan Yang
Journal:  IUBMB Life       Date:  2015-08-27       Impact factor: 3.885

Review 3.  MicroRNAs as novel therapeutic targets to treat kidney injury and fibrosis.

Authors:  Ivan G Gomez; Naoki Nakagawa; Jeremy S Duffield
Journal:  Am J Physiol Renal Physiol       Date:  2016-02-24

Review 4.  Therapeutic potential of microRNAs for the treatment of renal fibrosis and CKD.

Authors:  Wenshan Lv; Fan Fan; Yangang Wang; Ezekiel Gonzalez-Fernandez; Chen Wang; Lili Yang; George W Booz; Richard J Roman
Journal:  Physiol Genomics       Date:  2017-11-10       Impact factor: 3.107

5.  Effects of xanthine oxidase inhibition with febuxostat on the development of nephropathy in experimental type 2 diabetes.

Authors:  Radko Komers; Bei Xu; Jennifer Schneider; Terry T Oyama
Journal:  Br J Pharmacol       Date:  2016-07-27       Impact factor: 8.739

6.  MiR-135a promotes renal fibrosis in diabetic nephropathy by regulating TRPC1.

Authors:  Feng He; Fenfen Peng; Xi Xia; Chen Zhao; Qimei Luo; Weiming Guan; Zhijian Li; Xueqing Yu; Fengxian Huang
Journal:  Diabetologia       Date:  2014-06-09       Impact factor: 10.122

7.  The role of miR-200a in mammalian epithelial cell transformation.

Authors:  Lindsey E Becker; Apana Agha L Takwi; Zhongxin Lu; Yong Li
Journal:  Carcinogenesis       Date:  2014-09-19       Impact factor: 4.944

Review 8.  MicroRNAs in kidney physiology and disease.

Authors:  Piera Trionfini; Ariela Benigni; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2014-11-11       Impact factor: 28.314

Review 9.  miR-200c: a versatile watchdog in cancer progression, EMT, and drug resistance.

Authors:  Merve Mutlu; Umar Raza; Özge Saatci; Erol Eyüpoğlu; Emre Yurdusev; Özgür Şahin
Journal:  J Mol Med (Berl)       Date:  2016-04-20       Impact factor: 4.599

Review 10.  Diabetic nephropathy--emerging epigenetic mechanisms.

Authors:  Mitsuo Kato; Rama Natarajan
Journal:  Nat Rev Nephrol       Date:  2014-07-08       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.